L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
Taiho Oncology, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Cancer Research UK
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center
Servier
Assistance Publique - Hôpitaux de Paris
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Children's Oncology Group
Bambino Gesù Hospital and Research Institute
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Nanfang Hospital, Southern Medical University
Cancer Research UK
Cancer Research UK
Cancer Research UK
Cancer Research UK
Cancer Research UK
Cancer Research UK
Beijing InnoCare Pharma Tech Co., Ltd.
Monash University
Monash University
Monash University
Monash University
Actinium Pharmaceuticals
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Shanxi Bethune Hospital
Acacia Pharma Ltd
Institute of Hematology & Blood Diseases Hospital, China
National University of Malaysia
Medical College of Wisconsin
Institute of Hematology & Blood Diseases Hospital, China
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Universitätsklinikum Hamburg-Eppendorf
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
University of Giessen
The First Affiliated Hospital of Soochow University
University Hospital, Angers
Seoul St. Mary's Hospital
TG Therapeutics, Inc.
Monash University
The First Affiliated Hospital of Soochow University
The Second Affiliated Hospital of Kunming Medical University
Versailles Hospital